We could block every event in tumor progression by either VEGF-D or α9 knock down, such as tumor growth, tumor associated lymphangiogenesis, angiogenesis, and lymphatic metastasis, indicating the independent as well as combined roles of the ligand and the receptor in cancer progression in vivo. Here, IGKV1D-22 is linked to neoplasm.